Ameriprise
ACET icon

Ameriprise’s Adicet Bio ACET Stock Holding History

Ameriprise’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,095
Closed -$81.5K – 3884
2023
Q2 		$81.5K Buy
+2,095
New +$185K ﹤0.01% 3837

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Ameriprise's ACET Position: Q3 2023 in Review

Ameriprise sold out of Adicet Bio (ACET) in Q3 2023, closing a stake of 2,095 shares — an estimated $81.5K sold.

Ameriprise first reported a position in ACET in Q2 2023 and held it in 1 quarter. The position peaked at $81.5K in Q2 2023. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

  • Ameriprise reported no remaining Adicet Bio position as of Q3 2023 after selling out during the quarter.
  • Ameriprise sold 2,095 Adicet Bio shares in Q3 2023, an estimated $81.5K.
  • Ameriprise first reported a position in Adicet Bio in Q2 2023 and held it in 1 quarter.
  • Ameriprise's Adicet Bio position peaked at $81.5K in Q2 2023.
  • 83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.